Renhong Tang
699-18 Xuan Wu Avenue
Nanjing, 210042, China
Nanjing, 210042, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy.
Journal: Journal of medicinal chemistry
Published: December 30, 2025
PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer.
Journal: Molecular cancer therapeutics
Published: September 12, 2025
A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes.
Journal: Translational lung cancer research
Published: April 19, 2025
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.
Journal: Nature cancer
Published: April 09, 2025
Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma.
Journal: Cell reports. Medicine
Published: June 24, 2024
Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
Journal: The Journal of infection
Published: May 28, 2024
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors.
Journal: MedComm
Published: March 29, 2024
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Journal: The New England journal of medicine
Published: January 17, 2024
Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
Journal: Journal of medicinal chemistry
Published: December 21, 2023
Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology research.
Journal: International immunopharmacology
Published: December 15, 2023
Engineering cytokines for cancer immunotherapy: a systematic review.
Journal: Frontiers in immunology
Published: May 06, 2023
Last Updated: 09/26/2026